GEN3017 for Lymphoma

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: Any Age

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Genmab

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing GEN3017, a new injectable drug, in patients whose specific types of cancer have not responded to other treatments. The drug works by targeting and attacking cancer cells with a unique marker.

Eligibility Criteria

This trial is for adults with relapsed or refractory CD30-expressing Hodgkin and Non-Hodgkin Lymphomas, who have at least one measurable lesion. Participants should be in good physical condition (ECOG score 0-1) and not have received certain recent treatments like chemotherapy, major surgery, or investigational drugs.

Inclusion Criteria

My cancer is a relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma.

I have at least one tumor that can be measured on scans.

My tumor biopsy shows CD30-positivity.

I am over 18 and can care for myself with minimal assistance, or I am 16-18 with a good level of activity.

Exclusion Criteria

I haven't had chemotherapy in the last 2 weeks or major surgery in the last 4 weeks.

My cancer has spread to or originated in my brain.

I have had a stem cell transplant using my own cells within the last 60 days or a transplant from a donor.

I haven't taken high doses of steroids or immunosuppressants in the last 2 weeks.

Participant Groups

The trial tests GEN3017 as a solo treatment to see how safe it is and how well it works against lymphoma. It's given through under-the-skin injections. Everyone in the study will receive this active drug; there's no placebo group.

2Treatment groups

Experimental Treatment

Group I: R/R CD30+ cHL CohortExperimental Treatment1 Intervention

Group II: R/R CD30+ TCL CohortExperimental Treatment1 Intervention